688317.SHG Shanghai ZJ Bio-Tech Co. Ltd. A
- Market cap
- CNY 3.11B
- P/E
- -
- P/B
- 0.96x
- ROE
- -2.4%
- Dividend yield
- 0.10%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688317.SHG undervalued?
Graham numberThe Graham number of Shanghai ZJ Bio-Tech Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai ZJ Bio-Tech Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai ZJ Bio-Tech Co. Ltd. A yet.
Shanghai ZJ Bio-Tech Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. The company offers nucleic acid and real-time PCR kits, as well as consumables. It serves public health safety and clinical diagnostics sectors. The company was founded in 2005 and is based in Shanghai, China.
Full company profileShanghai ZJ Bio-Tech Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai ZJ Bio-Tech Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 157M | 193M | 224M | 259M | 2.05B | 2.02B | 2.33B | 274M | 179M | 125M | 112M |
| Gross Profit | 129M | 157M | 181M | 197M | 1.52B | 1.26B | 1.20B | -7.80M | -37.4M | 125M | 72.5M |
| Operating Income | 51.2M | 62.0M | 72.6M | 61.3M | 1.11B | 901M | 907M | -149M | -146M | -48.4M | -83.4M |
| EBITDA | 73.7M | 81.1M | 94.7M | 83.8M | 1.13B | 922M | 959M | -92.6M | -84.5M | 22.8M | -69.4M |
| Net Income | 48.7M | 51.5M | 62.3M | 51.5M | 932M | 759M | 760M | -137M | -127M | -34.3M | -77.6M |
| EPS | 0.33 | 0.35 | 0.43 | 0.35 | 6.38 | 3.98 | 3.93 | -0.71 | -0.67 | -0.19 | -0.41 |
| Balance Sheet | |||||||||||
| Total Assets | 527M | 516M | 580M | 642M | 1.88B | 4.25B | 4.74B | 4.07B | 3.79B | 3.76B | 3.61B |
| Total Liabilities | 42.7M | 43.4M | 47.0M | 70.1M | 417M | 427M | 543M | 249M | 153M | 415M | 390M |
| Shareholders' Equity | 484M | 473M | 533M | 572M | 1.46B | 3.83B | 4.20B | 3.82B | 3.64B | 3.35B | 3.22B |
| Cash & Short-term Investments | 96.7M | 208M | 266M | 246M | 1.20B | 2.94B | 3.15B | 2.77B | 2.78B | 2.55B | 2.31B |
| Total Debt | - | - | - | - | - | - | 8.63M | 7.45M | 4.93M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 44.5M | 48.0M | 80.6M | 76.7M | 1.14B | 642M | 585M | -81.9M | 77.6M | 66.9M | - |
| Capital Expenditure | 31.8M | 28.6M | 17.5M | 23.6M | 74.6M | 498M | 74.6M | 81.1M | 19.5M | 1.99M | 32.6M |
| Free Cash Flow | 12.7M | 19.4M | 63.1M | 53.1M | 1.07B | 144M | 510M | -163M | 58.1M | 64.9M | -20.4M |
| Ratios | |||||||||||
| ROE | 10.1% | 10.9% | 11.7% | 9.0% | 63.7% | 19.8% | 18.1% | -3.6% | -3.5% | -1.0% | -2.4% |
| ROA | 9.3% | 10.0% | 10.8% | 8.0% | 49.6% | 17.8% | 16.0% | -3.4% | -3.4% | -0.9% | -2.1% |
| Net Profit Margin | 31.1% | 26.7% | 27.8% | 19.9% | 45.4% | 37.6% | 32.7% | -49.9% | -71.3% | -27.5% | -69.1% |
| Debt to Equity | - | - | - | - | - | - | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai ZJ Bio-Tech Co. Ltd. A dividends
- Dividend yield
- 0.10%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Oct 18, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 3.03M | 0.02 | - |
| 2024 | CNY 20.9M | 0.11 | - |
| 2023 | CNY 231M | 1.20 | - |
| 2022 | CNY 266M | 1.37 | 34.9% |
| 2021 | CNY 312M | 1.63 | 41.1% |
| 2020 | CNY 65.7M | 0.45 | 7.1% |
| 2019 | CNY 65.7M | 0.45 | 127.5% |
| 2018 | 190K | 0.00 | 0.3% |
| 2017 | 58.4M | 0.40 | 113.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai ZJ Bio-Tech Co. Ltd. A
- Insiders 42.13%
- Institutions 2.23%
- Public & others 55.64%
- Shares outstanding 190M
- Free float 90.2M
Shanghai ZJ Bio-Tech Co. Ltd. A company profile
- Company name
- Shanghai ZJ Bio-Tech Co. Ltd. A
- Ticker
- 688317.SHG
- ISIN
- CNE100005DB6
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 275
- Fiscal year end
- December
- Address
- Pujiang Wisdom Plaza, Shanghai, China, 201114
- Phone
- 86 21 3468 0595
- Website
- liferiver.com.cn
About Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. The company offers nucleic acid and real-time PCR kits, as well as consumables. It serves public health safety and clinical diagnostics sectors. The company was founded in 2005 and is based in Shanghai, China.
Shanghai ZJ Bio-Tech Co. Ltd. A management
10- Mr. Junbin ShaoChairman, GM, Dean of Research Institute & Technology Development Center · born 1971
- Ms. Weiqin NiDeputy GM, Secretary, Acting CFO & Director · born 1981
- Mr. Kai WangDeputy General Manager · born 1982
- Mr. Yan LiuR&D Director · born 1983
- Mr. Yiyun WangDeputy General Manager · born 1980
- Mr. Feng ShuSynthesis Department Manager · born 1983
- Mr. Peixiao LiProduction Manager · born 1984
- Mr. Qinwei ZhuDirector of Product Development Center & Manager of Project Management Department · born 1982
- Hong Bing YuAccounting Supervisor
- Mr. Jie ZhangCore Technical Staff · born 1981